Steve joined ICON in early 2012 as the President of PriceSpective LLC. Over his past 12 years working as a health care consultant Steve held executive roles at PriceSpective, IMS Health and Cambridge Pharma Consultancy. During this time, Steve and his teams successfully completed over 400 projects spanning every important therapeutic area and geography.
Prior to his work in consulting, Steve’s tenure includes 12 years of pharmaceutical industry roles that included sales, market research, brand management and international operations with Eli Lilly, Merck and Pharmacia. He was also the leader of several international product launch teams.
Steve graduated with B.S Degrees in Marketing and International Business from the Leeds School of Business at the University of Colorado. He has also secured a Masters of Business Administration from Pepperdine University, Graziado school of Business and Management.
Brian is Vice President Operations for ICON Late Phase & Outcomes Research. Brian was Chief Operating Officer of Oxford Outcomes for 7 years prior to its acquisition by ICON in January 2011. In this capacity, Brian was responsible for all operations of the company in North America, including financial performance, market growth, strategy and planning. Prior to joining Oxford Outcomes Brian was the Director of Operations and Administration for the BC Centre for Excellence in HIV/AIDS in Vancouver. The Centre is a HIV/AIDS dedicated teaching and research organization that also bought and distributed all the HIV/AIDS drugs for the province of British Columbia.
Brian has a degree in Political Science, and diploma in Health Services Administration, and a Healthier Communities Fellowship
Ted joined ICON as a Partner at PriceSpective, following ICON’s acquisition of PriceSpective in February 2012. Ted had spent the previous 15 years working in the rapidly evolving field of global biopharmaceutical commercial analysis and strategy, with a focus on pricing and reimbursement, market access, and competitive opportunity assessment. With the experience of hundreds of consulting engagements, he has helped develop commercial strategies for products that range from treatments for the largest primary and specialty therapy areas, to novel and highly targeted agents for ultra-orphan diseases.
Ted joined PriceSpective in 2006 to help drive the firm’s expansion of content and geographic capabilities, in order to focus on his core pricing and reimbursement competencies. Prior to this, he founded and was Director of IMS Emerging Biopharma, where he provided strategic and tactical assistance to development-stage biopharmaceutical companies in support of their commercialisation and valuation processes. Previously, Ted was Vice President, IMS Management Consulting, US West, helping lead a team of consultants in a broad range of commercial strategy engagements. Before accepting that position, he had been Vice President with Cambridge Pharma Consultancy in both New York and San Francisco, focusing on value proposition development and US and global and pricing and reimbursement strategy.
Before joining IMS, Ted worked as an internal consultant in issues analysis for Pfizer’s Corporate Affairs department, on topics including Medicare reform, international pricing policy, and corporate branding. He then moved into Pfizer’s business intelligence function, focusing on the strategic positions of key in-line and pipeline products.
Ted has a BA from Middlebury College, an MA in International Public Policy from Tufts University, and MALD from the Fletcher School of Law & Diplomacy. He holds a Chartered Financial Analyst designation, and is a member of the Academy for Investment Management Research and the New York Society of Security Analysts.